Michael LaBarre
Chief Tech/Sci/R&D Officer at HALOZYME THERAPEUTICS, INC.
Net worth: 7 M $ as of 31/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Connie Matsui | F | 70 | 18 years | |
| Jeffrey Henderson | M | 59 | 9 years | |
| Helen Torley | M | 61 | 10 years | |
| Mark Snyder | M | 57 | 2 years | |
| Nicole LaBrosse | F | 41 | 9 years | |
| Barbara Duncan | F | 59 | 1 years | |
| Matthew Posard | M | 56 | 11 years | |
| Tram Bui | F | - | 2 years | |
| Akiko Miyashita | F | 68 | 2 years | |
| Bernadette Connaughton | F | 65 | 6 years | |
| Amy Marinne Fox | F | - | 4 years | |
| Steve Knowles | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregory Ian Frost | M | 52 | 16 years | |
| William Rastetter | M | 76 |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 19 years |
| Jonathan Lim | M | 52 | 7 years | |
| Kathryn Falberg | F | 63 | 9 years | |
| Richard Miller | M | 73 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 18 years |
| Harry Leonhardt | M | 67 | 5 years | |
| John Dunn | M | 72 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 1 years |
| Kenneth Kelley | M | 64 | 17 years | |
| David Ramsay | M | 59 | 12 years | |
| Kurt Gustafson | M | 56 | 4 years | |
| Masaru Matsuda | M | 53 | 3 years | |
| William R. Rohn | M | 80 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 12 years |
| Albert Kildani | M | - | - | |
| Jean Bizzari | M | 69 | 9 years | |
| James Daly | M | 63 | 8 years | |
| John Stuart Patton | M | 77 | 25 years | |
| James E. Cartoni | M | - | 3 years | |
| Robert Engler | M | 79 | 11 years | |
| Christine Anna White | M | 72 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 9 years |
| Eric S. Hoffman | M | 54 | 5 years | |
| William J. Fallon | M | - | 14 years | |
| Phillip Schneider | M | 67 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 16 years |
| Michael E. Paolucci | M | 64 | 5 years | |
| William Mccarthy | M | - | 9 years | |
| Homa Yeganegi | F | - | - | |
| Thomas Heineman | M | - | 2 years | |
| Jim Mazzola | M | - | 3 years | |
| Jonathan Leff | M | 66 | 1 years | |
| Randal Kirk | M | 70 | 11 years | |
| Jean Liu | F | 55 | 3 years | |
| Mark Wiggins | M | 68 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | - |
| William Young | M | 79 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | - |
| Christopher Watt | M | 59 | 11 years | |
| Michael E. Markels | M | - | 1 years | |
| Nicolas Barthelemy | M | 58 | 8 years | |
| Scott Anthony Climes | M | 59 | 2 years | |
| Maiken Keson-Brookes | F | 52 | 5 years | |
| Stephen Daly | M | - | - | |
| Sunil Joshi | M | - | 2 years | |
| Richard Francis | M | 55 | 8 years | |
| Laurie Stelzer | F | 56 | 5 years | |
| Ben Harshbarger | M | 55 | 5 years | |
| Andrea DiFabio | F | 55 | 11 years | |
| Robert J. Little | M | 74 | 4 years | |
| James Kelly | M | 58 | 5 years | |
| Schond Greenway | M | 52 | 3 years | |
| Dimitrios Chondros | M | 59 | 5 years | |
| Benjamin Hickey | M | 50 | 2 years | |
| James Basta | M | 58 | - | |
| David Mitchell | M | 67 | 4 years | |
| Joseph J. Kenny | M | - | 5 years | |
| Michael Pollock | M | - | 2 years | |
| Susie Melody | F | - | 2 years | |
| Jeff Knight | M | 53 | 1 years | |
| Mann Muhsin | M | - | 3 years | |
| Bethany Sensenig | F | 48 | 13 years | |
| Esther Alegria | M | 66 | 10 years | |
| Mark E. Erwin | M | 59 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 4 years |
| Robert Gagnon | M | 49 | 7 years | |
| Timothy Kelly | M | 55 | 7 years | |
| Robert W. Pangia | M | 72 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | - |
| Antonio J. Grillo-López | M | 84 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 11 years |
| Alan B. Glassberg | M | 87 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | - |
| Philip Gotwals | M | 61 | 2 years | |
| Arturo Molina | M | 65 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 1 years |
| David Hallal | M | 57 | 2 years | |
| David Parkinson | M | 73 | 1 years | |
| Stephen Tulipano | M | 65 | 8 years | |
| Matthew W. Onaitis | M | 53 | - | |
| Jim Shaffer | M | 57 | 3 years | |
| Katherine J. Turner | M | 70 | 4 years | |
| Bonne Adams | F | 47 | 2 years | |
| Melissa Morandi | F | 59 | 2 years | |
| Bruce R. Ross | M | 83 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | - |
| Faheem Hasnain | M | 65 | 4 years | |
| Robert Peach | M | 68 | 2 years | |
| E. J. Brandreth | M | - |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 7 years |
| Dinah Sah | M | 63 | 6 years | |
| Daniel Char | M | 63 | 11 years | |
| Pratik Multani | M | 57 | 5 years | |
| Akshay Vaishnaw | M | 61 | 7 years | |
| Douglas A. Abel | M | 62 | 4 years | |
| Alessandra Cesano | M | 63 | 2 years | |
| Anne Cook | F | 62 | 13 years | |
| Allen Kamer | M | 53 | 3 years | |
| Michael Gilman | M | 69 | 6 years | |
| Eric W. Kimble | M | 58 | 5 years | |
| Eugene Park | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael LaBarre
- Personal Network